Multicenter trials multiplicity

Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwinger T, Mitoxantrone in Multiple Sclerosis Study Group (MIMS)l (2002) Mitoxantrone in progressive multiple sclerosis A placebo-controlled, double-blind, randomized, multicenter trial. Lancet 360 2018-2025. 

Paty, D.W., and D.K. Li, Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 1993.43(4) 662-7. 

Based on the results from these three trials, BioCryst has initiated a multicenter Phase III trial for the treatment of CTCL, as well as a large, multicenter Phase II trial for psoriasis. In addition to the two clinical trials using the topical formulation, a Phase I clinical trial in CTCL and T-cell lymphoma/leukemia has begun using an oral formulation of BCX-34. In the future, a number of other T-cell mediated diseases or processes are possible targets for BCX-34, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and organ transplant rejection. 

Johnson BCP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Liska RP, Myers LW, Panitch HS, Rose JW, Schiffer TB, Vollmer T, Weiner LP, Wolinsky JS, Copolymer 1 Multiple Sclerosis Study Group (1995) Copolymer I reduces relapse rate and improves disability in relapsmg remitting multiple sclerosis Results of a phase HI multicenter double-blmd placebo-controlled trial. Neurol 45 1268—1276. 

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zalfaroni M, Independent Comparison of Interferon (INCOMIN) trial Study Group (2002) Every other day interferon beta-1 b versus once-weekly interferon beta-1 a for multiple sclerosis Results of a 2 year prospective, randomized multicenter study (INCOMIN). Lancet 35 1453-1460. 

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, et al. Longterm efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma a randomized, double-blind, multicenter, comparative trial. Cancer 2003 98 1735-1 744. 

First, the largest prospective trial to date to evaluate the diagnostic value of BNP is The Breathing Not Properly Multicenter Study, from which numerous publications have addressed multiple aspects regarding the utility of BNP monitoring. In this multinational trial, more... 

Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma results of a multicenter randomized controlled trial. J Clin Oncol 2001 19 3771-3779. 

Wang Y. Milnacipran for the treatment of fibromyalgia in adults a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008 30(11) 1988-2004. 

---